Indivior Pharmaceuticals Completes Merger with Supernus Pharmaceuticals
Indivior Pharmaceuticals (INDV) has officially completed its merger with peer Supernus Pharmaceuticals (SUPN), marking the end of Indivior's tenure as a standalone company. The transaction, which was originally announced in August, creates a diversified biopharmaceutical entity focused on the central nervous system (CNS) sector. Following the close, the combined business will operate under the Supernus name and ticker symbol. Under the terms of the deal, Indivior shareholders are set to receive a one-time special cash dividend of $1 billion. In exchange for their shares, Supernus investors received approximately 1.5 shares of Indivior common stock for every share held. The resulting entity is expected to be owned roughly 56.5% by former Indivior shareholders and 43.5% by Supernus investors. Management aims to realize $125 million in annual cost synergies through the integration.
Topics: biopharmaceutical industry merger completion special dividend stock ticker change
Read the full article at Motley Fool
Part of the story Indivior Pharmaceuticals Completes Merger with Supernus Pharmaceuticals (2 articles)